Renoprotective effects of telmisartan on renal injury in obese Zucker rats.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Angiotensin II Type 1 Receptor Blockers/*administration & dosage ; Benzimidazoles/*administration & dosage ; Benzoates/*administration & dosage ; Diabetes Mellitus, Type 2/*complications ; Diabetic Nephropathies/*drug therapy ; Diabetic Nephropathies/*prevention & control; Albuminuria/drug therapy ; Animals ; Cholesterol/metabolism ; Diabetic Nephropathies/metabolism ; Humans ; Kidney/drug effects ; Male ; Proteinuria/drug therapy ; Rats ; Rats, Zucker ; Telmisartan ; Triglycerides/metabolism ; Urine/chemistry
    • Abstract:
      The purpose of the present study was to investigate the renoprotective effect of telmisartan, an angiotensin II receptor antagonist, on the early stages of diabetic nephropathy in obese Zucker rats, which is a type 2-related diabetes mellitus model. Telmisartan 1, 3 or 10 mg/kg/day was orally administered to 7-week-old rats that demonstrated glucose tolerance without albuminuria or proteinuria, for 24 consecutive weeks (Experiment A). In another experiment (Experiment B), oral administration of telmisartan 10 mg/kg/day was initiated at the age of 16 weeks after the rats demonstrated marked proteinuria, and continued for 24 weeks. Telmisartan inhibited the increase in proteinuria and albuminuria in a dose-dependent manner, and the inhibition for all telmisartan groups was statistically significant by the completion of administration (Experiment A). Telmisartan also displayed similar inhibitory effects on proteinuria and albuminuria in Experiment B. Histologically, telmisartan [3 and 10 mg/kg/day] was associated with a significant decrease in the progression of glomerulosclerosis, and significantly improved interstitial cell infiltration, interstitial fibrosis and dilation and atrophy of renal tubules. Furthermore, telmisartan treatment was associated with a tendency towards normalized plasma lipids (total cholesterol and triglyceride). Our results suggest that telmisartan has a definite renoprotective effect against renal injury in type II diabetic nephropathy.
    • Accession Number:
      0 (Angiotensin II Type 1 Receptor Blockers)
      0 (Benzimidazoles)
      0 (Benzoates)
      0 (Triglycerides)
      97C5T2UQ7J (Cholesterol)
      U5SYW473RQ (Telmisartan)
    • Publication Date:
      Date Created: 20071117 Date Completed: 20130613 Latest Revision: 20181202
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s00592-007-0016-5
    • Accession Number:
      18008027